Meiogenix Announces Mary Beth Miranda as Chief Business Development Officer

Meiogenix, Inc, is pleased to announce the appointment of Mary Beth Miranda, Ph.D. as its new Chief Business Development Officer. With an extensive background spanning biotechnology, agriculture and innovation-driven industries, Mary Beth brings a wealth of expertise in technology strategy, business development and strategic partnerships. She has held leadership roles at Syngenta, Novozymes and Brightseed, successfully driving industry collaborations and accelerating market adoption of cutting-edge technologies. Mary Beth holds a Ph.D. in Chemical Engineering from the University of Wisconsin and a Bachelor of Science in Chemical Engineering and Applied Biology from the Massachusetts Institute of Technology (MIT).

“I’m thrilled to join Meiogenix at such a pivotal moment, as we leverage the power of targeted recombination to drive agricultural innovation and accelerate breakthroughs in climate resilience, stress tolerance and crop performance. With our technology and visionary team, Meiogenix is poised for transformative growth and I look forward to collaborating with our team members and partners to develop the next generation of crop varieties,” said Mary Beth Miranda.

Mary Beth’s appointment further strengthens Meiogenix’s leadership team as the company continues to advance its targeted recombination technology. Ricardo Garcia de Alba, CEO of Meiogenix, highlighted the significance of this milestone, stating, “Alongside Mary Beth, our CTO Dr. Gagan Sidhu, and our extraordinary team, we are committed to building Meiogenix into a leader in targeted recombination. Delivering advanced, differentiated crop varieties that empower farmers to tackle the pressing challenges of climate change, sustainability and food security.”

Neal Gutterson, Chairman of the Board at Meiogenix, added, “Mary Beth’s deep industry experience, strategic mindset, and impressive network will be instrumental as we expand Meiogenix’s impact. Her leadership will accelerate our mission to transform crop improvement and deliver real-world solutions for global agriculture. Our leadership team now has all the experience and capabilities to take Meiogenix to the next stage of its growth.”

With Mary Beth’s leadership, Meiogenix is poised to strengthen global partnerships, accelerate technology adoption, and realize the full commercial potential of our targeted recombination technology platform.

For more information on Meiogenix, please visit https://meiogenix.com/